Cardiff Oncology, Inc.
Company Stats
- Market Cap
- $94.1M
- as of Sep 30, 2026
- Shares Outstanding
- 77.8M
- Free Float
- 89.0%
Income Statement
- Revenue
- $593,000
- Operating Income
- -$49.0M
- Net Income
- -$45.9M
- EBITDA
- -$48.6M
- Revenue Growth, 3Y
- 15.4%
- FCF Margin, 3Y Avg
- -6127.2%
- FCF Margin, Worst Year
- -6448.6%
Cash Flow
- Free Cash Flow
- -$38.0M
- FCF Yield
- -40.3%
- Owner FCF Yield
- -46.4%
Balance Sheet
- Cash & Equivalents
- $17.5M
Returns & Capital
- SBC, 3Y Avg
- $5.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $593,000 | -$38.0M | -6402.5% |
| FY2024 | $683,000 | -$37.8M | -5530.5% |
| FY2023 | $488,000 | -$31.5M | -6448.6% |
| FY2022 | $386,000 | -$34.8M | -9022.3% |
| FY2021 | $359,000 | -$23.2M | -6474.9% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges